BioSpace News Archive

Masimo (NASDAQ: MASI) today announced the findings of a randomized, controlled trial published in the Journal of Clinical Anesthesia in which Dr. Melody H.Y. Long and colleagues from the KK Women’s and Children’s Hospital in Singapore evaluated the ability of electroencephalogram (EEG)-guided anesthesia, using Masimo SedLine® brain function monitoring, to reduce the amount of the drug sevoflurane needed to maintain anesthesia in pediatric patients undergoing minor surgery.

Forecast to 2030,’ thoroughly examines the Bronchiolitis industry to provide essential data & information for the targeted readers.

Forecast to 2030,’ thoroughly examines the Tinnitus Management industry to provide essential data & information for the targeted readers.

Spectral Instruments Imaging today announced the release of the DecaFlow Animal Management System.

CVR Medical Corp. is a healthcare company that operates in the medical device industry focused on the commercialization of its disruptive, proprietary Carotid Stenotic Scan device (the “CSS”).

According to the report, the global pulse electromagnetic field (PEMF) therapy devices market was valued at US$ 550 Mn in 2020 and is anticipated to expand at a CAGR of 3% from 2022 to 2030.

Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the second quarter 2022 after market close on Wednesday, August 10th, 2022.

ImmVira’s global first intravenous (“IV”) administered oncolytic herpes simplex virus (“oHSV”) product MVR-T3011 IV has completed the first three cohort escalation in the U.S. Phase I clinical trial, tested dosage from 1x106 to 1x108 PFU on 10 subjects with late-stage pancreatic, colon, lung, endometrial, breast, head and neck, gastrointestinal cancers and other advanced tumors.

Versanis Bio (“Versanis”), a clinical-stage company advancing novel therapeutics for cardiometabolic diseases, today announced three organizational appointments.

Aclarion, Inc. announced the launch of the Economic Value Analysis of Low back pain study; a rigorous healthcare economic study to assess the impact of the Nociscan solution on the cost of care for patients suffering from chronic low back pain.